{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019380","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2023-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.039943+00:00","generated_at":"2026-06-07T20:15:12.894998+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ReShape Lifesciences raises $1.2M via warrant exercise with existing accredited investor","bullets":["Gross proceeds ~$1.2M from exercise of 5,382,500 warrants at reduced price of $0.23/share.","New warrants issued for 10,765,000 shares (200% coverage) at $0.23, exercisable in 6 months for 5.5 years.","Exercise price of existing warrants reduced from $0.2503 to $0.23; also reduces price on 6,960,351 unexercised warrants.","Beneficial ownership limits: 9.99% for existing, 4.99% for new warrants.","Proceeds earmarked for commercial growth, working capital, and general corporate purposes. Maxim Group acted as agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019380","json":"https://secwatch.observer/filing/0001558370-23-019380.json","markdown":"https://secwatch.observer/filing/0001558370-23-019380.md","text":"https://secwatch.observer/filing/0001558370-23-019380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000155837023019380/0001558370-23-019380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000155837023019380/rsls-20231121x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:15:12.894998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14b4d5c89e15b0fd8ef8b0df34ed40146ae09f57","claim":"Vyome Holdings, Inc entered into warrant exercise agreement with an existing accredited investor valued at approximately $1.2 million (effective 2023-11-21).","evidence_excerpt":"On November 21, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000155837023019380/0001558370-23-019380-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an existing accredited investor"},{"label":"Value","value":"approximately $1.2 million"},{"label":"Effective","value":"2023-11-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}